Creative Planning Acquires 1,769 Shares of Henry Schein, Inc. $HSIC

Creative Planning increased its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 12.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,137 shares of the company’s stock after purchasing an additional 1,769 shares during the period. Creative Planning’s holdings in Henry Schein were worth $1,179,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new stake in Henry Schein in the second quarter worth $43,000. Steph & Co. purchased a new position in shares of Henry Schein in the second quarter worth about $44,000. CX Institutional increased its holdings in shares of Henry Schein by 107.3% in the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares during the period. TD Private Client Wealth LLC lifted its stake in shares of Henry Schein by 103.0% in the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock valued at $49,000 after acquiring an additional 339 shares during the last quarter. Finally, Quarry LP purchased a new stake in Henry Schein during the 1st quarter valued at about $71,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $74.66 on Friday. The firm has a market capitalization of $8.79 billion, a price-to-earnings ratio of 24.08, a PEG ratio of 2.06 and a beta of 0.84. The stock has a fifty day moving average of $67.74 and a 200 day moving average of $69.40. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

HSIC has been the topic of a number of analyst reports. Morgan Stanley lifted their price target on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Wells Fargo & Company upped their price target on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Finally, UBS Group decreased their price objective on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and an average target price of $76.08.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.